Decreased PCSK9 expression in human hepatocellular carcinoma

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Tumor metabolism and cholesterol regulation
• Biomarker discovery in oncology

Background:

• Hepatocellular carcinoma (HCC) management is hindered by a lack of effective screening biomarkers and chemotherapy options.
• Tumor metabolism, particularly cholesterol metabolism, is a promising therapeutic target for HCC.
• PCSK9 influences low-density lipoprotein receptor (LDL-R) internalization and hepatic cholesterol uptake, impacting liver regeneration.

Purpose of the Study:

• To investigate alterations in PCSK9 expression within HCC.
• To determine the relationship between PCSK9 expression and cholesterol metabolism in HCC.
• To assess the potential of PCSK9 as a therapeutic target for HCC.

Main Methods:

• Tissue microarrays (TMAs) were constructed from HCC and adjacent liver tissues of 39 patients.
• Immunohistochemistry was used to assess PCSK9 expression, with objective staining analysis.
• Quantitative RT-PCR and ELISA were employed to measure PCSK9 and LDL receptor mRNA and serum levels, respectively.

Main Results:

• HCC tissues exhibited significantly lower PCSK9 expression compared to adjacent cirrhotic tissues (p < 0.0001).
• Conversely, LDL receptor (LDL-R) expression was significantly higher in HCC tissues than in adjacent cirrhosis (p < 0.0001).
• Serum PCSK9 levels were elevated in HCC patients compared to those with chronic liver disease without HCC (p = 0.029).

Conclusions:

• The observed downregulation of PCSK9 and upregulation of LDL-R in HCC suggests a metabolic adaptation for sustained energy supply.
• These findings highlight the potential role of altered cholesterol metabolism in HCC progression.
• Further large-scale studies are warranted to validate PCSK9 as a potential therapeutic target for hepatocellular carcinoma.